$LEGN

Casey Patrick John sold $89K of LEGN

Casey Patrick John sold 6,000 shares of Legend Biotech Corp (LEGN) at $14.80 on 2026-06-30.

Original reporting
SEC EDGAR · Casey Patrick John
Published Jul 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 7:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LEGN
Neutral
medium confidence
Mentioned
$LEGN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LEGNNeutralLow
01

Why it matters

The disclosure indicates an open-market sale of 6,000 shares at $14.80 on June 30, with holdings after the transaction of 48,604 shares.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide a new operational or financial catalyst.

03

What to watch

The article provides only the sale size and post-transaction holdings, not total insider ownership changes, sale history, or whether other insiders sold/bought around the same time.

Relevance 3/10Novelty 3/10Timing: Form 4 filed July 2, covering a June 30 sale.

Background

This is an SEC Form 4 insider transaction disclosure for Legend Biotech director Casey Patrick John.

Company-level read

Ticker impact

$LEGNNeutralMedium confidence
Context

Legend Biotech director Casey Patrick John sold 6,000 shares in an open-market transaction for about $88.8K, per Form 4 filed July 2.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing discloses a small-to-moderate dollar value sale by a director, with no accompanying company-specific catalyst (earnings, guidance, deal, or regulatory action).

Market effects

Minimal; this is company-specific insider transaction data, not a sector-wide signal.

None.

None.

Counterpoint

Insider sales are often planned for diversification or liquidity needs; the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • Legend Biotech Corp

    Company whose director insider sale is disclosed on Form 4.

  • Casey Patrick John

    Director who sold 6,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LEGNHighAI 8/10

Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?

Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M, up from $255.1M, and net income of $33.2M, reversing a prior loss. H1 2026 revenue was $692.6M, with net loss reduced to $21.1M. The company projects $2.2B revenue and $464.7M earnings by 2029. Analysts highlight CARVYKTI's role in profitability and pipeline assets. Management changes and CARVYKTI's dominance remain key risks.

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657M (+50% YoY), with U.S. $472M (+32%) and ex-U.S. $185M (+128%). Total revenue was $387.5M (+52%), adjusted net income $63.1M ($0.16/share), and cash $965M. Q3 gross margin guidance was lower-50% range.

$LEGNMed

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) fell 2.4% in pre-open trading after a Q2 2026 earnings beat. Adjusted EPS was $0.16 versus $0.07 consensus, and revenue was $387.5 million versus $362.81 million expected, with the company reporting its first quarter of company-wide profitability. Oppenheimer downgraded it to Perform and cut its price target to $40 from $75, citing competitive pressure on CARVYKTI and limited near-term catalysts.

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657 million, up 50% YoY. Total revenue was $387.5 million, up 52% YoY, with adjusted net income of $63.1 million ($0.16/share). Cash was $965 million. Q3 gross margin guidance was in the lower 50% range.